Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3

Conditions

Carcinoma, Ovarian Epithelial 3

Interventions

Paclitaxel 32Carboplatin 23liposomal doxorubicin 14pembrolizumab 12Topotecan 10Bevacizumab 10Gemcitabine 9mirvetuximab soravtansine 8olaparib 6Cisplatin 61-dodecylpyridoxal 6rucaparib 5Nivolumab 5Cyclophosphamide 5oregovomab 4farletuzumab 3catumaxomab 3Standard of Care 3Irinotecan 3Fulvestrant 3CCV-AV protocol 3talazoparib 2sacituzumab govitecan 2ribociclib 2phenoxodiol 2pegfilgrastim 2pazopanib 2palbociclib 2niraparib 2fludarabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Ovarian Epithelial × CCV-AV protocol × Clear all
NCT01617629 2017-12-08

CAN-003X

Prima BioMed Ltd

Phase 2 Completed
9 enrolled 7 charts
Gynecologic

Carcinoma, Ovarian Epithelial

NCT01068509 2017-05-11

Ovarian Cancer Vaccine for Patients in Remission

Prima BioMed Ltd

Phase 2 Completed
63 enrolled 9 charts
Gynecologic

Carcinoma, Ovarian Epithelial

NCT01521143 2016-12-14

CANVAS

Prima BioMed Ltd

Phase 2 Terminated
91 enrolled 5 charts
Gynecologic

Carcinoma, Ovarian Epithelial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡